Infection Outcomes Assessment of Absorbable Antibacterial Soft Tissue Support in Breast Reconstruction

Overview

About this study

The purpose of this study is to demonstrate the safety and effectiveness of the Melodi Absorbable Antibacterial Matrix for soft tissue support in immediate, two-stage postmastectomy alloplastic prepectoral breast reconstruction, to support an FDA Premarket Approval (PMA) Application.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Subject is a genetic female.
  • Subject is ≥ 22 years of age at the time of enrollment.
  • Subject is scheduled to undergo either unilateral or bilateral mastectomy (including prophylactic) with immediate, two-stage post-mastectomy alloplastic prepectoral breast reconstruction. 
  • Subject is able and willing to comply with the protocol requirements, has been informed of the nature of the study, and has signed the IRB-approved informed consent form.

Exclusion Criteria

  • Subject has prior history of neoadjuvant radiotherapy.
  • Subject has had prior history of failed tissue expansion or breast implantation at the intended reconstruction site.
  • Subject has an active abscess or infection requiring antibiotics anywhere in their body within 30 days prior to informed consent.
  • Subject has a Body Mass Index (BMI) < 14 or > 40.
  • Subject is pregnant or is nursing; or plans to become pregnant during the course of the study.
  • Subject has any connective tissue/autoimmune disorder or rheumatoid disease, such as systemic lupus erythematosus, discoid lupus, scleroderma, or rheumatoid arthritis.
  • Subject has known allergies to study device materials (poly [lactic acid, co-glycolic acid]), tyrosine-based polyarylate coating, rifampin and minocycline antibacterial agents), or lactide and glycolide copolymer sutures (e.g., Vicryl®).
  • Subject is participating in another interventional research study that may interfere with study endpoints.
  • Subject has limited life expectancy or co-morbid conditions, social/psychological problems, or cognitive impairments that, in the opinion of the Investigator, will preclude them from participation and completion of study procedures or requirements.
  • Subject has a medical condition or is taking medications that would result in elevated risk (e.g., blood clotting), and/or affect the validity of the study as determined by the Investigator; or any other clinical reasons deemed by the Investigator to make the patient an unsuitable candidate for the study.
  • Intraoperative assessment demonstrates unfavorable conditions (i.e., poor mastectomy skin flap thickness or viability) for immediate, two-stage post-mastectomy alloplastic prepectoral reconstruction in any breast.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/12/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Aparna Vijayasekaran, M.B.B.S.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available